“…The first is about ibrutinib treatment for mantle cell lymphoma patients in the time of COVID-19 from a clinical observation point of view, [9] while the second discussed special aspects of COVID-19 management in patients during autologous stem cell transplant for autoimmune diseases. [10] …”